AMANDA RAY: Open Payments
NPI 1831652080 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$950 in 45 payments from 12 companies in 2025. Trend: 2023 $488 · 2024 $527 · 2025 $950
Food & beverage: $950
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $227 |
| Otsuka America Pharmaceutical, Inc. | 9 | $169 |
| Alkermes, Inc. | 8 | $156 |
| Neurocrine BioSciences, Inc. | 4 | $98 |
| Teva Pharmaceuticals USA, Inc. | 3 | $67 |
| ABBVIE INC. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Bausch Health US, LLC | 2 | $33 |
| Tris Pharma Inc | 1 | $22 |
Products named: COBENFY, REXULTI, ARISTADA, INGREZZA, VRAYLAR, CAPLYTA, UZEDY, Auvelity.
Industry payments across TX — which companies pay providers there.
